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AThere is a great lack of efficient treatments for membranoproliferative glomerulonephritis (MPGN) and recently
emerged complement therapies have been proposed to be useful. We report a patient with a complement-
mediatedMPGN having recurrencies in kidney allografts and an unsuccessful treatmentwith complement inhib-
itor, eculizumab (anti-C5 monoclonal antibody). Nephritic factor (C3Nef), an autoantibody against C3bBb, in the
patient serum activated C3 but not C5 showing that major damage was mediated by C3 activation with clearly
less involvement of C5 explaining unresponsiveness to eculizumab. Analyzing C3Nef-mediated C3 and C5 activa-
tion separately could help in choosing the right patients for eculizumab therapy.





Understanding the etiology of MPGN has gone through amajor shift
leading also to a new classification in recent years. The newest classifi-
cation relying on immunofluorescence microscopy (IF) divides it into
two subtypes: complement-mediated (C3 and no or very little immuno-
globulins) and immune-complex-mediated (IF showing both C3 and
immunoglobulins) [1]. The former will arise following dysregulation
of the alternative pathway (AP) of complement and the latter as a result
of ongoing antigenemia due to chronic infection, paraproteinemia, auto-
immune disease or miscellaneous reasons. C3 glomerulopathies (C3G)
refer to complement-mediated MPGN that can be further subclassified
into dense deposit disease (DDD) and C3 glomerulonephritis (C3GN)
by electron microscopy (EM). Both DDD and C3GN are rare diseases of
dysregulation of the alternative pathway. They are either due to muta-
tions in complement components or autoantibodies against C3bBb
(C3Nef) or factor H or rarely factor B [2]. Due to strong AP activation
the levels of complement activation products are elevated andC3 is con-
sumed in the plasmas of C3G patients [3]. C3Nef is detected in the ma-
jority of patients with DDD and approximately in half of the patients
with C3GN [4,5].
Currently, there is no therapeutic agent of proven efficacy for C3G.
Supportive measures, occasional trials of plasma therapy and immune
suppression have been reported with varying results [6]. PreliminaryHelsinki, Finland.results using the complement inhibitor, eculizumab, were promising,
especially in cases with elevated blood levels of SC5b-9, the soluble
form of the terminal complement complex. Improvements in renal var-
iableswere seen in about 60% of patients, and the results did not seem to
depend on the type of C3G [7–11]. However, upstream activation at the
C3 level continues even though C5 and downstream terminal pathway
activation are completely blockedwith eculizumab. Extensive C3 activa-
tion could thereby cause substantial progression of the disease [3,12]. It
would be important to differentiate C3G patients likely to respond to
eculizumab from those not responding without a treatment trial with
off-label use of expensive medication.
2. Methods
Complement analyses were carried out at HUSLAB, an accredited
laboratory of the Helsinki University Hospital. Complement component
levels (C3, C4) were determined by nephelometry. The Wielisa® test
was used for determination of activities of the classical, lectin and alter-
native complement pathways (Euro-Diagnostica, Malmö, Sweden).
Plasma soluble terminal complement complex (p-SC5b-9) was ana-
lyzed at the Department of Medical Microbiology and Immunology,
Turku University by a sandwich-ELISA-test with a murine monoclonal
anti-human SC5b-9 (Quidel) as a capture-antibody. The SC5b-9 com-
plex is recognized by polyclonal C5 and C7 antibodies and detected by
a HRP-conjugated secondary antibody. Complement gene mutation
analyses were performed by Secugen S.L. in Madrid, Spain. Factor H an-
tibodies were analyzed by an in-house ELISA technique and factor H-
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technique using a polyspecific anti-human CFH antibody at the Depart-
ment of Bacteriology and Immunology, University of Helsinki. C3Nef
analysis was performed by incubating patient serum with fresh normal
human serum in veronal-buffered saline (VBS) or 5 mMMgCl2, 10 mM
EGTA-VBS or in 10 mM EDTA-VBS at 37 °C for 30 min. Subsequent C3
and C5 cleavage were analyzed by immunoblotting after electrophore-
sis in agarose or SDS-PAGE gels using rabbit antibodies against human
C3c or C5 from Quidel.
Kidney histology was examined at the Transplantation Laboratory,
Department of Pathology, Helsinki University Hospital. Hematoxylin
and eosin (HE), Periodic Acid Schiff (PAS) and Jones Silver stainings
were used for LM. Deposition of complement components C1q, C4d,
C3 and immunoglobulins (IgG, IgM) in cryostat kidney sections were
analyzed by indirect IF microscopy.
3. Case report and results
Amale patient, currently 37 years old, was diagnosed with MPGN
type I already at the age of 16 in 1993. Kidney function was lost in the
coming years and hemodialysis was started in 1997. The patient re-
ceived the 1st cadaveric kidney transplantation in 1998, with con-
ventional triple immunosuppression (cyclosporine, azathioprine
and corticosteroids) and an immediate good graft function. Several
kidney biopsies were performed in the coming years and a clear de-
position of C3 was observed in the mesangial areas in 2002. Hemodi-
alysis was restarted in 2003. The 2nd cadaveric transplantation was
performed in 2006 with tacrolimus, mycophenolate mofetil and cor-
ticosteroids based immunosuppression with an immediate good
graft function. Protocol biopsy at 3 months showed weak IgM and a
clear C3 staining in glomeruli. Allograft function was normal, but
both hematuria and proteinuria were increasingly evident. Another
biopsy at 12 months showed clear signs of MPGN with strong
glomerular staining for C3 and some IgM. Allograft dysfunction
developed along with nephrotic range proteinuria and hematuria.
Oral cyclophosphamide was started for 2 months, plasma exchanges
were instituted, tacrolimus and corticosteroids weremaintained and
mycophenolate mofetil was stopped. Due to a lack of response ritux-
imab was started with no apparent response. Finally, home
hemodialysis was started in 2009.
The 3rd cadaveric transplantation took place in April 2013, but
the patient remained dependent on dialysis afterwards. Transplant
baseline biopsy was normal. The 2nd biopsy 18 days post-
transplantation showed acute tubular necrosis (ATN) in large areas.
Glomerular endothelial basement membranes showed slight
damage indicating MPGN recurrence. No IF analysis was performed.
The 3rd biopsy at 25 days showed ATN in some areas and also clear
MPGN with C3 in the capillaries and mesangium with no immuno-
globulins, C1q or C4d. Several transplant biopsies were taken during
the coming months all showing increasing MPGN changes and C3 in
the glomeruli. Eventually ATN vanished, and no signs of rejection or
inflammation were detected. In the last biopsy all glomeruli showed
typical features of MPGN, but no significant atrophy, fibrosis or
inflammation was present. C4d staining was negative, C3 was
strongly positive in the glomerular capillaries and mesangium. EM
showed extensive glomerular damage, but the podocytes were
reasonably well preserved. On the basis of EM the diagnosis of C3
glomerulonephritis was confirmed.
Complement inhibitor eculizumab, a humanized anti-C5 anti-
body (Soliris®, Alexion, Cheshire, USA), was started in the beginning
of July 2013, nine weeks after the transplantation with a protocol
similar to that used in atypical hemolytic-uremic syndrome
(aHUS). The patient remained dialysis-dependent all the time, but
the frequency was reduced to twice weekly one month after starting
the eculizumab treatment. Triple immunosuppression (corticoste-
roids, mycophenolate mofetil and tacrolimus) was continued duringeculizumab therapy. Predialysis serum creatinine was 4.1 mg/dl,
daily urinary protein excretion 315 mg/24 h and urine dipstick
showed hematuria at the time of starting eculizumab treatment.
Predialysis serum creatinine was at its lowest varying between 3.7
and 3.9 mg/dl three months after starting eculizumab. However, a
disturbed acid-base balance necessitated medication between the
dialysis sessions. Three times a week schedule was restarted after
approximately 5 months of eculizumab treatment due to progressive
deterioration of the fluid status and increasing creatinine levels.
Eculizumab was discontinued after 6 months due to a poor response.
Currently, the patient is performing home hemodialysis 4 h every
other day.
Complement investigations before the start of complement in-
hibitor therapy showed increased levels of p-SC5b-9 3525 ng/ml
(ref b 725 ng/ml). Total complement activities of the classical, lectin
and alternative pathways were within the reference range, but the
level of plasma C3 was decreased (0.69 g/l; ref. 0.71–1.41), plasma
C4 was normal and C3Nef was constantly positive. Sequence analysis
of complement factor H (CFH), factor I (CFI), membrane cofactor pro-
tein (MCP, CD46), factor B (CFB), C3, diacylglycerol kinase ε (DGKE)
and thrombomodulin (THBD) genes revealed no mutations. How-
ever, in the MCP gene, a heterozygous aHUS risk haplotype and sev-
eral risk polymorphisms in CFB and C3 and one known
polymorphism in THBD were observed, but they were not consid-
ered significant. No deficiencies of FHR-1-5 proteins or anti-factor
H antibodies were detected. We next analyzed complement activa-
tion by mixing and incubating (30 min at 37 °C) the patient's
serum (taken when not under eculizumab treatment) with normal
serum from a healthy volunteer. Analysis by SDS-PAGE and immuno-
blotting with specific polyclonal antisera showed that C3 became ac-
tivated, but C5 not in the serum mixture. The result suggests that
C3Nef in the patient was of the type that in solution activates C3
but not C5.
Eculizumab blocked activities of all the complement activation
pathways and reduced p-SC5b-9-levels significantly. C3Nef
remained constantly positive and plasma C3 level never increased
to normal levels. This was as expected considering that eculizumab
acts at the C5 level in the complement cascade. A series of light
microscopy (LM) and IF analyses of C3 clearly show the evolution
of C3G/MPGN histology before and during eculizumab treatment
(Figs. 1 and 2).
4. Discussion
Our patient seemed to benefit from eculizumab treatment during
the first few months of therapy. Plasma level of p-SC5b-9 was ini-
tially increased and subsequently decreased after the start of
eculizumab treatment and there was no major chronic damage
seen in a kidney biopsy in the beginning raising the hope for a
treatment response with eculizumab. However, repeated kidney
biopsies showed a progressive MPGN-type glomerular injury and
the clinical benefit was minimal. If eculizumab had been started
earlier, the benefit could have been greater, but not necessarily
substantial.
The patient was regularly positive for C3 nephritic factor, an
autoantibody that stabilizes the AP C3 convertase C3bBb.Wewanted
to analyze whether continuous overactivation of C3 was the primary
problem as complement C5-driven injury seemed to be efficiently
blocked by eculizumab. Therefore, we carried out further comple-
ment analysis to determine whether C5 could have been involved
in the complement-driven renal damage. When incubating the
patient's serum with that of a healthy person a substantial C3
activation, but no C5 activation was observed. This was compatible
with the course of the disease as eculizumab has no impact on
complement activation before C5. This is in linewith a similar finding
as eculizumab added in vitro to serum of DDD patient did not
Fig. 1. Follow-up kidney biopsies show progressive glomerular damage despite treatmentwith eculizumab. The findings include signs of acute tubular necrosis, the first two pictures have
acute tubular necrosis while the last two don't (HE 200x), accumulation of PAS-positive material and obstruction of capillaries (PAS 200x), thickening of basement membranes in Jones
Silver staining (Jones Silver 400x) and increasingdeposition of complement C3 in the capillarywalls (C3c 400x). Pre-ecu=before eculizumab treatment, post-ecu× 2=after two doses of
eculizumab, post-ecu × 7 = after seven doses of eculizumab, post-ecu × 14 = after 14 doses of eculizumab.
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[13]. The fact that the plasma level of SC5b-9 was initially elevated
in our patient could be due to the activity of the C5 convertasemostly
as a cell surface enzyme complex.
The result suggests that C3Nef in the patient was of the type that
in solution activates C3 but not C5. We therefore propose that
methods dissecting C3 and C5 activation could be employed to assess
which patients would be likely to benefit from the off-label use of
eculizumab therapy without having to reach that conclusion after a
treatment trial.Fig. 2. Electronmicrograph demonstrating subendothelial deposits (★) in biopsy after 14
doses of Ecu.Disclosures
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